TY - JOUR
T1 - Valve Replacement in Children
T2 - Guidelines for Selection of Prosthesis and Timing of Surgical Intervention
AU - Ilbawi, Michel N.
AU - Idriss, Farouk S.
AU - DeLeon, Serafin Y.
AU - Muster, Alexander J.
AU - Duffy, C. Elise
AU - Gidding, Samuel S.
AU - Paul, Milton H.
PY - 1987
Y1 - 1987
N2 - One hundred fifty-nine patients ranging from 3 months to 18 years old (mean, 8.1 ± 3.7 years) underwent 162 primary valve implantations. A porcine valve was used in 104 patients, a St. Jude Medical valve in 40, and a Björk-Shiley valve in 18. The valve replaced was the aortic in 25 patients, the mitral (systemic atrioventricular [AV] valve) in 43, the pulmonary in 71, and the tricuspid (pulmonary AV valve) in 23. Hospital mortality was 6%. Patients with a Björk-Shiley valve received warfarin sodium anticoagulation, and those with a St. Jude Medical valve were given salicylates and dipyridamole. Follow-up is available on all patients 0.6 to 12 years postoperatively (mean, 6.3 ± 2.6 years). New York Heart Association Functional Class improved in 62% and remained unchanged in 38% of the patients. Thromboembolic complications occurred in only 8 (57%) of 14 patients with a St. Jude Medical valve in the right (pulmonary) side and in 3 (12%) of 26 with the valve in the left (systemic) side of the circulation. Bacterial endocarditis developed in 3 patients, all with porcine valves. Early valve replacement, less than 2 years after detection of hemodynamic deterioration, resulted in improvement in the ventricular ejection fraction in 25 of 29 patients (from 81 ± 14% to 90 ± 12% of normal; p < 0.05). In contrast, the ejection fraction remained abnormal in all 22 patients with delayed valve insertion (more than 2 years) (81 ± 16% of normal preoperatively and 80 ± 10% of normal following operation; p = not significant). Actuarial functional life, free from all prosthesis-related complications including major hemodynamic abnormalities, was 92 ± 6% for right-sided and 67 ± 8% for left-sided porcine valves versus 47 ± 3% for right-sided and 88 ± 7% for left-sided St. Jude Medical valves at 5 years. The data indicate that the St. Jude Medical valve has excellent durability and hemodynamic function in the left (systemic) side without need of warfarin anticoagulation. The good long-term performance of right-sided (pulmonary circulation) porcine valves encourages their continued use for tricuspid and pulmonary valve replacements. Timely valve insertion can preserve myocardial function.
AB - One hundred fifty-nine patients ranging from 3 months to 18 years old (mean, 8.1 ± 3.7 years) underwent 162 primary valve implantations. A porcine valve was used in 104 patients, a St. Jude Medical valve in 40, and a Björk-Shiley valve in 18. The valve replaced was the aortic in 25 patients, the mitral (systemic atrioventricular [AV] valve) in 43, the pulmonary in 71, and the tricuspid (pulmonary AV valve) in 23. Hospital mortality was 6%. Patients with a Björk-Shiley valve received warfarin sodium anticoagulation, and those with a St. Jude Medical valve were given salicylates and dipyridamole. Follow-up is available on all patients 0.6 to 12 years postoperatively (mean, 6.3 ± 2.6 years). New York Heart Association Functional Class improved in 62% and remained unchanged in 38% of the patients. Thromboembolic complications occurred in only 8 (57%) of 14 patients with a St. Jude Medical valve in the right (pulmonary) side and in 3 (12%) of 26 with the valve in the left (systemic) side of the circulation. Bacterial endocarditis developed in 3 patients, all with porcine valves. Early valve replacement, less than 2 years after detection of hemodynamic deterioration, resulted in improvement in the ventricular ejection fraction in 25 of 29 patients (from 81 ± 14% to 90 ± 12% of normal; p < 0.05). In contrast, the ejection fraction remained abnormal in all 22 patients with delayed valve insertion (more than 2 years) (81 ± 16% of normal preoperatively and 80 ± 10% of normal following operation; p = not significant). Actuarial functional life, free from all prosthesis-related complications including major hemodynamic abnormalities, was 92 ± 6% for right-sided and 67 ± 8% for left-sided porcine valves versus 47 ± 3% for right-sided and 88 ± 7% for left-sided St. Jude Medical valves at 5 years. The data indicate that the St. Jude Medical valve has excellent durability and hemodynamic function in the left (systemic) side without need of warfarin anticoagulation. The good long-term performance of right-sided (pulmonary circulation) porcine valves encourages their continued use for tricuspid and pulmonary valve replacements. Timely valve insertion can preserve myocardial function.
UR - http://www.scopus.com/inward/record.url?scp=0023615978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023615978&partnerID=8YFLogxK
U2 - 10.1016/S0003-4975(10)63800-3
DO - 10.1016/S0003-4975(10)63800-3
M3 - Article
C2 - 3662688
AN - SCOPUS:0023615978
SN - 0003-4975
VL - 44
SP - 398
EP - 403
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -